INT1646

From wiki-pain
(Difference between revisions)
Jump to: navigation, search
(Generated page)
 

Latest revision as of 03:02, 24 September 2012

Context Info
Confidence 0.58
First Reported 1973
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 17
Total Number 18
Disease Relevance 7.36
Pain Relevance 3.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (FSHR) plasma membrane (FSHR) signal transducer activity (FSHR)
Anatomy Link Frequency
follicle 4
pituitary 4
sperm 4
Sertoli cells 2
pituitary gland 2
FSHR (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 20 99.72 Very High Very High Very High
antagonist 55 99.38 Very High Very High Very High
opiate 2 98.76 Very High Very High Very High
Opioid 5 97.92 Very High Very High Very High
Clonidine 6 97.12 Very High Very High Very High
agonist 84 96.72 Very High Very High Very High
Dopamine 4 94.92 High High
Endogenous opioid 6 93.60 High High
Somatostatin 1 86.32 High High
headache 6 78.72 Quite High
Disease Link Frequency Relevance Heat
Reprotox - General 1 43 99.40 Very High Very High Very High
Anovulation 14 98.48 Very High Very High Very High
Stress 4 96.52 Very High Very High Very High
Adverse Drug Reaction 2 96.44 Very High Very High Very High
Reprotox - General 3 53 96.00 Very High Very High Very High
Galactorrhea 17 94.96 High High
Prolactinoma 5 93.44 High High
Overnutrition 1 92.80 High High
Reprotox - General 2 22 90.56 High High
Immunotherapy Of Cancer 4 88.12 High High

[edit] Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The elimination half-life of FSH obtained from cases received abdominal SC injections was very similar to those of previous studies employing fully suppressed pituitary endogenous FSH secretion.
Negative_regulation (suppressed) of Localization (secretion) of FSH in pituitary
1) Confidence 0.58 Published 2009 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2764710 Disease Relevance 0 Pain Relevance 0
The unusual selective inhibition of FSH secretion should be considered a valuable hormonal finding for the diagnosis of inhibin B-secreting adrenocortical tumors.


Negative_regulation (inhibition) of Localization (secretion) of FSH
2) Confidence 0.45 Published 2007 Journal Horm. Res. Section Body Doc Link 16974107 Disease Relevance 0 Pain Relevance 0
Oral contraceptive mechanisms include 1) blockage of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, 2) alteration of motility in the fallopian tubes 3) modification of endometrial maturation, and 4) rendering the cervical mucus hostile to sperm migration.
Negative_regulation (blockage) of Localization (release) of follicle-stimulating hormone in sperm
3) Confidence 0.42 Published 1973 Journal Am J Pharm Section Abstract Doc Link 12306537 Disease Relevance 0.78 Pain Relevance 0.14
Oral contraceptive mechanisms include 1) blockage of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, 2) alteration of motility in the fallopian tubes 3) modification of endometrial maturation, and 4) rendering the cervical mucus hostile to sperm migration.
Negative_regulation (blockage) of Localization (release) of FSH in sperm
4) Confidence 0.42 Published 1973 Journal Am J Pharm Section Abstract Doc Link 12306537 Disease Relevance 0.78 Pain Relevance 0.14
There are three classes of anovulation, ie, WHO I, WHO II and WHO III.15–17 Women with WHO class I anovulation, which accounts for 10% of anovulatory women, have low or low–normal serum FSH concentrations and low serum estradiol concentrations due to decreased hypothalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unresponsiveness to GnRH.
Negative_regulation (decreased) of Localization (secretion) of FSH in pituitary associated with anovulation
5) Confidence 0.39 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971716 Disease Relevance 0.86 Pain Relevance 0
The results obtained point also to a possible different pattern of LH and FSH secretion after naloxone, that is after opiate receptor blockade.
Spec (possible) Negative_regulation (pattern) of Localization (secretion) of FSH associated with narcan and opiate
6) Confidence 0.35 Published 1979 Journal Neurosci. Lett. Section Abstract Doc Link 223091 Disease Relevance 0 Pain Relevance 0.93
These results demonstrate that in normal women during the midluteal phase of the menstrual cycle, CRH inhibits the secretion of both LH and FSH.
Negative_regulation (inhibits) of Localization (secretion) of FSH
7) Confidence 0.30 Published 1989 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2493035 Disease Relevance 0.08 Pain Relevance 0.41
Prolactin inhibits the release of LH and FSH, directly impairing testosterone production [5].
Negative_regulation (inhibits) of Localization (release) of FSH
8) Confidence 0.23 Published 2008 Journal J Med Case Reports Section Body Doc Link PMC2490703 Disease Relevance 1.27 Pain Relevance 0.16
The Sertoli cells of the testes, in addition to stimulating spermatogenesis, also secrete the glycoprotein hormone inhibin, which provides negative feedback to the pituitary, inhibiting the secretion of FSH (11).
Negative_regulation (inhibiting) of Localization (secretion) of FSH in Sertoli cells
9) Confidence 0.20 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948422 Disease Relevance 0 Pain Relevance 0
These directions for research would include: confirming the available preliminary data on the success of aromatase inhibition in induction and augmentation of ovulation, as well as reducing the dose of FSH needed for ovarian stimulation, improving response in poor responders, and finding the optimum regimen for administering aromatase inhibitors for infertility treatment
Negative_regulation (reducing) of Localization (dose) of FSH associated with reprotox - general 3
10) Confidence 0.17 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.56 Pain Relevance 0.04
Confirming previous observations, a 5-h iv CRH (rat/human CRH, 100-150 micrograms/h), but not saline, infusion inhibited both LH and FSH secretion.
Negative_regulation (inhibited) of Localization (secretion) of FSH
11) Confidence 0.12 Published 1989 Journal Endocrinology Section Abstract Doc Link 2494035 Disease Relevance 0 Pain Relevance 0
Addition of naloxone to CRF prevented the CRF-mediated suppression of LH and FSH release.
Negative_regulation (suppression) of Localization (release) of FSH associated with narcan
12) Confidence 0.11 Published 1987 Journal Endocrinology Section Abstract Doc Link 3113919 Disease Relevance 0 Pain Relevance 0.38
GnRH receptor antagonists (blockers) are a new class of endocrine therapy that bind directly to the GnRH receptor, rapidly blocking the release of both LH and FSH, and thereby reducing testosterone secretion (Figure 1).20–25 In contrast to the agonists, GnRH antagonists do not cause an initial stimulation of LH production, and therefore do not cause testosterone surge or clinical flare.12 Abarelix was the first GnRH antagonist to be licensed for prostate cancer treatment; however, this agent was associated with immediate-onset systemic allergic reactions resulting from histamine release, and so is currently marketed only in Germany.26
Negative_regulation (blocking) of Localization (release) of FSH associated with antagonist, hypersensitivity, agonist and immunotherapy of cancer
13) Confidence 0.08 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004563 Disease Relevance 0.91 Pain Relevance 0.40
With longer-term administration, a resetting of the anterior pituitary receptor occurs, with subsequent reduction in LH along with follicle-stimulating hormone (FSH) release, resulting in achievement of castrate levels of testosterone (Conn et al 1984).
Negative_regulation (reduction) of Localization (release) of FSH in follicle
14) Confidence 0.06 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504071 Disease Relevance 0.30 Pain Relevance 0
These agents cause a reversible suppression of the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the anterior pituitary gland.
Negative_regulation (suppression) of Localization (release) of FSH in gland
15) Confidence 0.06 Published 1997 Journal Psychopharmacol Bull Section Abstract Doc Link 9230649 Disease Relevance 0.35 Pain Relevance 0.30
The LHRH antagonist D-pGlu1, D-Phe2,D-Trp3,6-LHRH blocked the secretion of Dyn A1-13-IR, LH, and FSH induced by hpGHRH-(1-44), whereas the LHRH antagonist did not influence the simultaneous GH release elicited by hpGHRH-(1-44).
Negative_regulation (blocked) of Localization (secretion) of FSH associated with antagonist
16) Confidence 0.05 Published 1987 Journal Endocrinology Section Abstract Doc Link 2879724 Disease Relevance 0 Pain Relevance 0.31
Suckling induces a reduction in gonadotropin releasing hormone, luteinizing hormone and follicle stimulating hormone release, resulting in amenorrhea, through an intracerebral opioid pathway: beta-endorphins inhibit gonadotropin releasing hormone and dopamine secretions, which, in turn stimulates prolactin secretion and milk production.
Negative_regulation (reduction) of Localization (release) of stimulating hormone in follicle associated with dopamine, opioid and reprotox - general 1
17) Confidence 0.00 Published 1997 Journal Eur J Contracept Reprod Health Care Section Abstract Doc Link 9678098 Disease Relevance 0.34 Pain Relevance 0.15
Subsequently, the reduced secretion of luteinizing hormone (LH) and follicular stimulating hormone (FSH) from the pituitary gland leads to ovarian suppression, which in turn can lead to hypoestrogenism.
Negative_regulation (reduced) of Localization (secretion) of follicular stimulating hormone in pituitary gland
18) Confidence 0.00 Published 2010 Journal Sports Med Arthrosc Rehabil Ther Technol Section Body Doc Link PMC2844364 Disease Relevance 1.13 Pain Relevance 0.11

[edit] General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox